A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

NCT01358968 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: LY2603618
DRUG: Desipramine
DRUG: Pemetrexed
DRUG: Gemcitabine

Sponsor

Eli Lilly and Company